Adherium's Capital Raising Announcement

Adherium Limited (ASX: $ADR) has secured commitments to raise up to $8.37 million through a placement and non-renounceable entitlement offer. The company aims to utilize the funds for research, product development, sales, marketing, business development, overseas expansion, staffing, customer onboarding, scale up, and working capital.

Executive Commentary on Capital Raising

Adherium CEO, Dr. Paul Mastoridis, emphasized the company's focus on extending the reach and impact of their respiratory health product portfolio within the US, the largest healthcare market. The capital raising will support their clear and focused US engagement and market penetration strategy, prioritizing manufacturing activities and sales via established pharmaceutical and payor groups in the US. Dr. Mastoridis highlighted Adherium's position as a global leader in digital health solutions, with multiple FDA clearances and US reimbursement codes in place, providing a competitive advantage.

Summary of Adherium's Capital Raising

Adherium Limited (ASX: $ADR) has successfully secured commitments to raise up to $8.37 million through a placement and non-renounceable entitlement offer. The funds raised will primarily be used to fast track US commercialization of Adherium's Hailie Smartinhaler® technology, which has multiple FDA clearances and US reimbursement codes in place. The company aims to extend the reach and impact of their respiratory health product portfolio within the US, the largest healthcare market. Adherium's ambitions include prioritizing manufacturing activities and sales via established pharmaceutical and payor groups in the US, leveraging their position as a global leader in digital health solutions. The capital raising reflects the company's strategic focus on US market penetration and product development, underlining their commitment to advancing respiratory health solutions.